After Q2 losses Kiniksa expects full-year profit
Kiniksa Pharmaceuticals Ltd, the Bermudian-based biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, has reported a net loss of $20 million in the second quarter.
That compares with a net loss of $41.6 million for the second quarter of 2021.
Total net revenue for Arcalyst product sales in the second quarter was $27 million, compared with $7.7 million for the second quarter a year ago.
Total operating expenses were $46.3 million, compared with $48.3 million for the second quarter of 2021.
Collaboration expense was $3.7 million. Kiniksa did not report a collaboration expense in the second quarter of 2021.
As of June 30, the company had $138.2 million of cash, cash equivalents, short-term investments and no debt.
Sanj K. Patel, chairman and chief executive officer of Kiniksa, said: “The continued momentum of Arcalyst in recurrent pericarditis in the second quarter of 2022 provides conviction in our full-year expectation for net revenue of between $115 to $130 million.
“Additionally, we believe the strong performance of Arcalyst since launch supports incremental investment to broaden our reach and help even more patients suffering from recurrent pericarditis.”
Need to
Know
2. Please respect the use of this community forum and its users.
3. Any poster that insults, threatens or verbally abuses another member, uses defamatory language, or deliberately disrupts discussions will be banned.
4. Users who violate the Terms of Service or any commenting rules will be banned.
5. Please stay on topic. "Trolling" to incite emotional responses and disrupt conversations will be deleted.
6. To understand further what is and isn't allowed and the actions we may take, please read our Terms of Service